Ractigen Therapeutics
Suzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A Chinese RNA therapeutics pioneer developing saRNA drugs to upregulate proteins for genetic diseases and oncology.
Genetics & GenomicsOncology
Technology Platform
A proprietary small activating RNA (saRNA) platform and associated delivery technologies designed to upregulate gene expression.
Opportunities
Pioneering a new class of RNA medicine with the potential to treat diseases caused by insufficient protein production.
Risk Factors
Unproven clinical safety and efficacy of the saRNA modality, coupled with the universal challenge of targeted RNA delivery in vivo.
Competitive Landscape
Operates in a nascent but competitive global field of RNA activation, competing with firms like MiNA Therapeutics and aiming to differentiate from dominant RNA silencing companies.